Search research articles
Contact Us
Filters
Showing results (201-210 of 221) with videos related to
Page
of 23
Sort By:
Communications Biology
|
February 6, 2021
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
Maeva Dufies, Annelies Verbiest, Lindsay S Cooley, et al.
JAMA Oncology
|
February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
Stéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Nizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Nature Medicine
|
June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine
|
March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial
Karim Fizazi, Francois Lesaunier, Remy Delva, et al.
Nature Medicine
|
November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
The New England Journal of Medicine
|
June 5, 2018
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Urologic Oncology
|
June 20, 2015
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features
Romain Mathieu, Géraldine Pignot, Alexandre Ingles, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 221) with videos related to
Sort By:
Page
of 23
Communications Biology
|
February 6, 2021
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
Maeva Dufies, Annelies Verbiest, Lindsay S Cooley, et al.
JAMA Oncology
|
February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
Stéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Nizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Nature Medicine
|
June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine
|
March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial
Karim Fizazi, Francois Lesaunier, Remy Delva, et al.
Nature Medicine
|
November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
The New England Journal of Medicine
|
June 5, 2018
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Urologic Oncology
|
June 20, 2015
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features
Romain Mathieu, Géraldine Pignot, Alexandre Ingles, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 23